吉非替尼靶向治疗表皮生长因子受体基因敏感突变的晚期非小细胞肺癌的疗效及安全性  

Efficacy and safety of gefitinib targeted therapy for patients with EGFR sensitive mutation advanced non-small cell lung cancer

作　　者：石功亮[1] 颜艳倩 SHI Gongliang;YAN Yanqian(The First People's Hospital of Chenzhou,Chenzhou 423000,China)

机构地区：[1]湖南省郴州市第一人民医院,423000

出　　处：《临床合理用药杂志》2021年第36期1-3,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的分析吉非替尼靶向治疗表皮生长因子受体(EGFR)基因敏感突变的晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法将2018年1月—2021年1月郴州市第一人民医院收治的70例EGFR基因敏感突变的晚期NSCLC患者纳入本研究,按照随机数字表法分为对照组和试验组,各35例。对照组患者给予艾迪注射液的同时采取GP方案治疗,试验组患者给予吉非替尼靶向治疗。2组均以3周为1个疗程,持续化疗2个疗程。比较2组临床疗效,治疗前后血清肿瘤标志物〔糖链抗原125(CA125)、鳞状上皮细胞癌相关抗原(SCCA)、癌胚抗原(CEA)及肿瘤坏死因子(TNF)〕水平及毒副作用发生率。结果试验组患者治疗总有效率为48.57%(17/35),高于对照组的31.43%(11/35)(P<0.001)。治疗前2组患者血清CA125、SCCA、CEA及TNF水平比较,差异无统计学意义(P>0.05);治疗后试验组患者血清CA125、SCCA、CEA及TNF水平低于对照组(P<0.05)。试验组患者毒副作用总发生率为5.71%(2/35),低于对照组的14.29%(5/35)(P<0.05)。结论吉非替尼靶向治疗EGFR基因敏感突变的晚期NSCLC患者的临床疗效确切,能有效降低患者血清肿瘤标志物水平,减轻毒副作用的发生。Objective To analyze the efficacy and safety of gefitinib targeted therapy for patients with EGFR sensitive mutation advanced non-small cell lung cancer(NSCLC).Methods A total of 70 patients with patients with EGFR sensitive mutation advanced NSCLC were selected from January 2018 to January 2021.They were divided into control group and experimental group according to the random number table method,with 35 cases in each group.The control group was treated with Aidi injection and GP regimen,and the experimental group was treated with gefitinib targeted therap.Both groups took 3 weeks as a course of treatment and continued chemotherapy for two courses.The clinical efficacy,the levels of serum tumor markers(CA125,SCCA,CEA and TNF)before and the treatment and the incidence of toxic and side effects were compared between the two groups.Results The total effective rate in the experimental group was 48.57%(17/35),which was higher than 31.43%(11/35)in the control group(P<0.001).There was no significant difference in serum levels of CA125,SCCA,CEA and TNF between the two groups before treatment(P>0.05);after treatment,theserum levels of CA125,SCCA,CEA and TNF in the experimental group were lower than those in the control group(P<0.05).The total incidence of toxic and side effects in the experimental group was 5.71%(2/35),which was lower than 14.29%(5/35)in the control group(P<0.05).Conclusion Gefitinib targeted therapy for patients with EGFR sensitive mutation advanced NSCLC has definite clinical efficacy,which can effectively reduce the serum levels of tumor markers and reduce the occurrence of toxic and side effects.

关 键 词：非小细胞肺癌 晚期 EGFR基因敏感突变 吉非替尼 靶向治疗 治疗结果 安全性 

分 类 号：R734.2[医药卫生—肿瘤]